A-beta Pathways: Uptake & Degradation
Click on one of the boxes below to see how these cells affect A-beta uptake and degradation.
Get Print CopyUse our Product Suggestion form to enter a request.
You will be notified once it becomes available.
Use our Product Suggestion form to enter a request.
You will be notified once it becomes available.
Use our Product Suggestion form to enter a request.
You will be notified once it becomes available.
Use our Product Suggestion form to enter a request.
You will be notified once it becomes available.
Use our Product Suggestion form to enter a request.
You will be notified once it becomes available.
Use our Product Suggestion form to enter a request.
You will be notified once it becomes available.
Use our Product Suggestion form to enter a request.
You will be notified once it becomes available.
Use our Product Suggestion form to enter a request.
You will be notified once it becomes available.
A-beta uptake
& degradation
A-beta uptake
& degradation
M/CD11b
M/CD11b
Component C3
Component C3
A-beta uptake
& degradation
A-beta uptake
& degradation
A-beta uptake
& degradation
A-beta uptake
& degradation
Overview of A-beta Uptake & Degradation
Amyloid-beta protein (A-beta) is the proposed causative agent of Alzheimer's disease (AD). One of the neuropathological hallmarks of AD is the accumulation of senile plaques in the brain. Senile plaques represent extracellular deposits of aggregated A-beta. Prior to its deposition as senile plaques, A-beta oligomerizes to exert pathological actions on neuron function and viability. AD therapies that are in the advanced stages of development mostly target A-beta production, aggregation, or clearance. Although most clinical trials focus on the treatment of symptomatic patients, it has been suggested that earlier intervention or disease prevention would be a more effective strategy. Research studies have investigated receptors that are involved in the uptake of A-beta (i.e. APP, CD36, FPRL, LDL R, LRP1, alpha-2-Macroglobulin, MARCO, SR-A1, and RAGE) and enzymes that are known to degrade A-beta (i.e. ACE, Cystatin C, ECE, Insulysin/IDE, MMPs, and Neprilysin). In fact, a recent report suggested that a combinatorial therapy designed to block A-beta production and enhance A-beta clearance might represent the most effective approach.
To learn more, please visit our APP Cleavage and Amyloid-beta Degradation Research Area.
Get Print Copy of this Pathway
